MedPath
FDA Approval

Bortezomib

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
BluePoint Laboratories
DUNS: 985523874
Effective Date
May 16, 2022
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Bortezomib(3.5 mg in 1 1)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Qilu Pharmaceutical (Hainan) Co., Ltd.

BluePoint Laboratories

529131725

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Bortezomib

Product Details

NDC Product Code
68001-540
Application Number
ANDA210824
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS, SUBCUTANEOUS
Effective Date
May 16, 2022
MANNITOLInactive
Code: 3OWL53L36AClass: IACTQuantity: 35 mg in 1 1
Code: 69G8BD63PPClass: ACTIBQuantity: 3.5 mg in 1 1
© Copyright 2025. All Rights Reserved by MedPath